Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Символ: 002399.SZ
SHZ
8.73
CNYПазарна цена днес
56.9451
Съотношение P/E
1.3830
Коефициент PEG
11.56B
MRK Cap
- 0.01%
Доходност на DIV
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399-SZ) финансови отчети
Баланс
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 11323.97 | 3450.4 | 3925.4 | 3540.6 | |||||||||||||||||
balance-sheet.row.short-term-investments | 2529.38 | 1311.6 | 981.2 | 828.2 | |||||||||||||||||
balance-sheet.row.net-receivables | 6671.92 | 1946.6 | 1985.5 | 2136.1 | |||||||||||||||||
balance-sheet.row.inventory | 30340.39 | 6843.9 | 4707.5 | 3168.2 | |||||||||||||||||
balance-sheet.row.other-current-assets | 850.89 | 148.7 | 151.2 | 283.8 | |||||||||||||||||
balance-sheet.row.total-current-assets | 49187.18 | 12389.6 | 10769.7 | 9128.7 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 10104.73 | 2477.3 | 2537.2 | 2571.5 | |||||||||||||||||
balance-sheet.row.goodwill | 9533.42 | 2351 | 2152.2 | 2202.6 | |||||||||||||||||
balance-sheet.row.intangible-assets | 2231.77 | 571.7 | 586.7 | 631 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 11765.2 | 2922.6 | 2738.9 | 2833.6 | |||||||||||||||||
balance-sheet.row.long-term-investments | 6836.49 | 1152.5 | 1636.7 | 3170.4 | |||||||||||||||||
balance-sheet.row.tax-assets | 572.54 | 139.6 | 121.7 | 83.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 3879.09 | 1732.5 | 1304.1 | 1237.8 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 33158.04 | 8424.6 | 8338.5 | 9897.2 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 82345.22 | 20814.2 | 19108.2 | 19025.9 | |||||||||||||||||
balance-sheet.row.account-payables | 1499.92 | 427.4 | 385.8 | 239.2 | |||||||||||||||||
balance-sheet.row.short-term-debt | 15317.7 | 4056.5 | 3299.9 | 2507.6 | |||||||||||||||||
balance-sheet.row.tax-payables | 509.86 | 141.8 | 158.7 | 90.5 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 9587.71 | 2407.4 | 2354.3 | 3137.5 | |||||||||||||||||
Deferred Revenue Non Current | 129.77 | 32.5 | 16.7 | 18.7 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1308.89 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 3125.64 | 658 | 3.8 | 3.6 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 11252.81 | 2830.8 | 2793.4 | 3724.1 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 404.19 | 110.7 | 104 | 51.6 | |||||||||||||||||
balance-sheet.row.total-liab | 32473.22 | 8406.6 | 7584.9 | 7336.9 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 5869.18 | 1467.3 | 1467.3 | 1467.3 | |||||||||||||||||
balance-sheet.row.retained-earnings | 17301.51 | 4314.1 | 3647 | 3674.9 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 8321.02 | 843.4 | 563.9 | 694 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 17998.75 | 5686.1 | 5733.2 | 5733.2 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 49490.46 | 12310.9 | 11411.4 | 11569.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 82345.22 | 20814.2 | 19108.2 | 19025.9 | |||||||||||||||||
balance-sheet.row.minority-interest | 381.54 | 96.7 | 112 | 119.6 | |||||||||||||||||
balance-sheet.row.total-equity | 49872 | 12407.6 | 11523.3 | 11689 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 82345.22 | - | - | - | |||||||||||||||||
Total Investments | 9365.86 | 2464.1 | 2617.8 | 3998.6 | |||||||||||||||||
balance-sheet.row.total-debt | 24905.41 | 6463.9 | 5654.2 | 5645.1 | |||||||||||||||||
balance-sheet.row.net-debt | 16110.82 | 4325.1 | 2709.9 | 2932.7 |
Отчет за паричните потоци
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 217.99 | 714.7 | 233.4 | 1021.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 96.93 | 307.7 | 302.7 | 304 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 3.98 | -43.3 | -170.6 | 172.7 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 887.34 | 43.3 | 0.2 | 0.3 | |||||||||||||||||
cash-flows.row.change-in-working-capital | -2327.66 | -2311.3 | -1125.1 | -765.4 | |||||||||||||||||
cash-flows.row.account-receivables | -176.1 | -176.1 | 141.8 | -346.7 | |||||||||||||||||
cash-flows.row.inventory | -2151.56 | -2151.6 | -1520.2 | -763.9 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 59.7 | 423.9 | 172.5 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -43.3 | -170.6 | 172.7 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 1242.76 | 532.3 | 752.7 | -695.9 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 121.35 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -334.7 | -222.4 | -193.9 | -212.5 | |||||||||||||||||
cash-flows.row.acquisitions-net | 2.32 | 0 | 1.7 | 0.2 | |||||||||||||||||
cash-flows.row.purchases-of-investments | -2416.02 | -4482.7 | -2370.2 | -1763.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 3173.85 | 4210.7 | 3305.1 | 1027 | |||||||||||||||||
cash-flows.row.other-investing-activites | 1134.37 | 744.2 | -22.9 | -1225 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 1559.82 | 249.8 | 719.9 | -2173.8 | |||||||||||||||||
cash-flows.row.debt-repayment | -6506.11 | -6036.3 | -3730.6 | -5197.4 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | -291.99 | -251 | -412.5 | -447.5 | |||||||||||||||||
cash-flows.row.other-financing-activites | 5485.35 | 6616.8 | 3642 | 8151.4 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1312.75 | 329.6 | -501.1 | 2506.5 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 38.52 | 17.3 | -62.8 | -116.3 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 14.27 | -159.9 | 149.4 | 253.7 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 6268.69 | 1319.7 | 1479.6 | 1330.2 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6254.42 | 1479.6 | 1330.2 | 1076.5 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 121.35 | -756.6 | -6.6 | 37.3 | |||||||||||||||||
cash-flows.row.capital-expenditure | -334.7 | -222.4 | -193.9 | -212.5 | |||||||||||||||||
cash-flows.row.free-cash-flow | -213.35 | -979 | -200.5 | -175.2 |
Ред за отчет за приходите
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5827.47 | 7159.4 | 6365.2 | 5332.1 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 3891.14 | 4825 | 4332.1 | 3244.3 | |||||||||||||||||
income-statement-row.row.gross-profit | 1936.32 | 2334.4 | 2033 | 2087.8 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 237.77 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 130.17 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 552.3 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 315.95 | 294.7 | 274.9 | 241.3 | |||||||||||||||||
income-statement-row.row.operating-expenses | 1230.9 | 1211.9 | 1068.9 | 961 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 5122.04 | 6036.9 | 5401 | 4205.2 | |||||||||||||||||
income-statement-row.row.interest-income | 61.02 | 54.1 | 54.9 | 34.6 | |||||||||||||||||
income-statement-row.row.interest-expense | 239.18 | 235.2 | 201.6 | 247.7 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 552.3 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 4.4 | -305.3 | -550.9 | -2.1 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 315.95 | 294.7 | 274.9 | 241.3 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 4.4 | -305.3 | -550.9 | -2.1 | |||||||||||||||||
income-statement-row.row.interest-expense | 239.18 | 235.2 | 201.6 | 247.7 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 239.02 | 307.7 | 302.7 | 632.8 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 404.55 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 165.53 | 1135.1 | 773.2 | 1330 | |||||||||||||||||
income-statement-row.row.income-before-tax | 169.93 | 829.9 | 222.3 | 1327.8 | |||||||||||||||||
income-statement-row.row.income-tax-expense | -36.58 | 115.2 | -11.1 | 306.2 | |||||||||||||||||
income-statement-row.row.net-income | 217.99 | 727.1 | 240.8 | 1024.2 |
Често задавани въпроси
Какво е Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) общи активи?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) общите активи са 20814206782.000.
Какъв е годишният приход на предприятието?
Годишните приходи са 2762211379.000.
Какъв е маржът на печалбата на предприятието?
Маржът на печалбата на фирмата е -0.145.
Какъв е свободният паричен поток на компанията?
Свободният паричен поток е -0.145.
Какъв е маржът на нетната печалба на предприятието?
Маржът на нетната печалба е 0.037.
Какъв е общият приход на предприятието?
Общият приход е 0.028.
Каква е Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) нетна печалба (нетен доход)?
Нетната печалба (нетният доход) е 727077671.000.
Какъв е общият дълг на фирмата?
Общият дълг е 6463902582.000.
Какъв е броят на оперативните разходи?
Оперативните разходи са 1211852274.000.
Какъв е броят на паричните средства на фирмата?
Паричните средства на предприятието са 1791292771.000.